BALVERSA is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has<\/p>\n
Select patients for therapy based on an FDA-approved companion diagnostic for BALVERSA.
\nThis indication is approved under accelerated approval based on tumor response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.<\/p>\n
Balversa (erdafitinib tablets) for oral use Initial U.S. Approval: 2019
\nTo access erdafitinib tablets sold under the brand name can be made available on request to patient if the drug has not been approved or is not available in your country. For information or advice, call IPN’s Pharmaceutical Expert. Our expert will be happy to take your query and guide with an effective solution. Be free and call today for full support at +91 9891 296 838 (Mr. Tarun) \/ +91 9811 747 774 (Mr. Neeraj)<\/p>\n","protected":false},"excerpt":{"rendered":"
Balversa (erdafitinib) is a medication used for the treatment of patients with locally advanced or metastatic urothelial carcinoma.<\/p>\n
Disease Indications-Urothelial Carcinoma If you have a prescription from a Registered Medical Practitioner (RMP),\u00a0IPN<\/a> in Delhi can assist you in obtaining access to genuine medication.\u00a0 Our professional will provide you with a step-by-step guide on how to legally and safely import \u201cErdafitinib Tablets\u201d based on the information you provide.<\/strong><\/p>\n
\nManufacturer-Janssen Pharmaceutica
\nUsage-Oral
\nMedicine Approved By-Food and Drug Administration (FDA), Health Canada
\nSummary of FDA-approved use on approval date: Click Here<\/a>
\n(see Drugs@FDA for complete indication)<\/p>\nAccess the best support services globally<\/h4>\n